| Targeting cancer with small molecule kinase inhibitors J Zhang, PL Yang, NS Gray Nature reviews cancer 9 (1), 28-39, 2009 | 3306 | 2009 |
| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2620 | 2017 |
| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2568 | 2012 |
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, ... Journal of Biological Chemistry 284 (12), 8023-8032, 2009 | 2041 | 2009 |
| A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1757 | 2016 |
| A unifying model for mTORC1-mediated regulation of mRNA translation CC Thoreen, L Chantranupong, HR Keys, T Wang, NS Gray, DM Sabatini Nature 485 (7396), 109-113, 2012 | 1589 | 2012 |
| DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival TR Peterson, M Laplante, CC Thoreen, Y Sancak, SA Kang, WM Kuehl, ... Cell 137 (5), 873-886, 2009 | 1584 | 2009 |
| Rational design of inhibitors that bind to inactive kinase conformations Y Liu, NS Gray Nature chemical biology 2 (7), 358-364, 2006 | 1332 | 2006 |
| A chemical switch for inhibitor-sensitive alleles of any protein kinase AC Bishop, JA Ubersax, DT Petsch, DP Matheos, NS Gray, J Blethrow, ... nature 407 (6802), 395-401, 2000 | 1260 | 2000 |
| EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ... Clinical cancer research 14 (13), 4275-4283, 2008 | 1230 | 2008 |
| The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling PP Hsu, SA Kang, J Rameseder, Y Zhang, KA Ottina, D Lim, TR Peterson, ... science 332 (6035), 1317-1322, 2011 | 1208 | 2011 |
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ... Nature 462 (7276), 1070-1074, 2009 | 1180 | 2009 |
| Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors NS Gray, L Wodicka, AMWH Thunnissen, TC Norman, S Kwon, ... Science 281 (5376), 533-538, 1998 | 1136 | 1998 |
| Activating mutations in ALK provide a therapeutic target in neuroblastoma RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ... Nature 455 (7215), 975-978, 2008 | 1017 | 2008 |
| Systematic identification of culture conditions for induction and maintenance of naive human pluripotency TW Theunissen, BE Powell, H Wang, M Mitalipova, DA Faddah, J Reddy, ... Cell stem cell 15 (4), 471-487, 2014 | 957 | 2014 |
| YY1 is a structural regulator of enhancer-promoter loops AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ... Cell 171 (7), 1573-1588. e28, 2017 | 876 | 2017 |
| Kinase inhibitors: the road ahead FM Ferguson, NS Gray Nature reviews Drug discovery 17 (5), 353-377, 2018 | 863 | 2018 |
| Targeting transcription regulation in cancer with a covalent CDK7 inhibitor N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ... Nature 511 (7511), 616-620, 2014 | 843 | 2014 |
| The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 837 | 2015 |
| MEK1 mutations confer resistance to MEK and B-RAF inhibition CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, ... Proceedings of the National Academy of Sciences 106 (48), 20411-20416, 2009 | 769 | 2009 |
